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http:WHAT THIS PAPER ADDS
In line with the growing interest in studying potential associations between daily (sedentary) physical activity
and its impact on cardiovascular risk reduction and mortality, this study is one of the ﬁrst to assess the effect of
supervised exercise therapy on walking behavior, ambulatory activities, and daily physical activity in patients
with intermittent claudication. The results of this study demonstrate the potential of this type of outcome
parameter in future studies and may stimulate its application in clinical practice.Objective/Background: Intermittent claudication (IC) is associated with a reduction in physical activity (PA) and a
more rapid functional decline leading to a higher mortality rate compared with healthy individuals. Supervised
exercise therapy (SET) is known to increase the walking capacity of patients with IC. However, it is unclear
whether SET increases PA. The aim of this study was to investigate the effect of SET on PA levels and ambulatory
activities in patients with IC.
Methods: Patients newly diagnosed with IC were requested to wear an activity monitor 1 week prior to and 1
week immediately after 3 months of SET. The primary outcome was the percentage of patients meeting the
minimum recommendations of PA (American College of Sports Medicine [ACSM]/American Heart Association
[AHA] recommendation for public health of  67 metabolic equivalents [METs]/min/day, in bouts of  10 min) at
baseline and after 3 months of SET. Additionally, daily PA level (METs/min), duration of ambulatory activities,
daily number of steps, pain free walking distance (PFWD), maximal walking distance (MWD), and Short Form
Health Survey (SF-36) health surveys were compared before and after SET.
Results: Data from 41 participants were available for analysis. A higher number of participants met the ACSM
minimum recommendation for PA at the 3 month follow up (baseline: 43%; 3 months: 63%; p ¼ .003). Despite
signiﬁcant increases in PFWD (baseline: 210 m; 3 months: 390 m; p ¼ .001), MWD (baseline: 373 m; 3 months:
555 m; p ¼ .002) and physical functioning score (SF-36) following SET, no increase in the mean daily PA level was
found (395  220 vs. 411  228 METs/min; p ¼ .43). Furthermore, the total number of steps and time spent in
ambulatory activities did not change following SET.
Conclusion: Three months of SET for IC leads to more patients meeting the ACSM/AHA public health minimum
recommendations for PA. Assessment of PA could be incorporated as an outcome parameter in future research
comparing different treatment modalities for peripheral arterial disease.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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//dx.doi.org/10.1016/j.ejvs.2014.11.002of life (QoL), and higher mortality rates.1 Primary treatment
of IC includes supervised exercise therapy (SET), as sug-
gested by several international guidelines.1e3 SET signiﬁ-
cantly improves the maximal (MWD) and pain free walking
distances (PFWD), and is cost effective.4e8 However, the
question arises whether the effectiveness of treatment
modalities for peripheral arterial disease (PAD) should be
evaluated on the basis of changes in walking capacity only.
Individuals who are regularly physically active report
better overall health, lower healthcare expenditure, and
fewer mobility limitations than their sedentary
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the American College of Sports Medicine (ACSM) provide
speciﬁc recommendations of various types of activity to
stimulate the elderly. Tailored recommendations are pro-
vided that apply to adults with clinically signiﬁcant chronic
conditions or functional limitations that affect mobility and
activity.11 Guidelines suggest engaging in aerobic exercise of
moderate intensity for a minimum of 30 min, 5 days a week,
or a minimum of 20 min of vigorous intensity activity 3 days
a week, or some combination of the two.11 Activities should
be performed in bouts of at least 10 min. Intensity of effort
is assessed in absolute terms by estimating the actual
metabolic cost of a given activity and assigning intensity
accordingly.12 A metabolic equivalent (MET) is an estimate
of oxygen consumption at rest. A three MET activity would
be an activity that utilizes roughly three times the amount
of resting energy expenditure. Accordingly, vigorous in-
tensity activities (> 6.0 METs) performed for a particular
duration and frequency generate greater energy expendi-
ture than moderate intensity activities (3.0e6.0 METs) of
the same duration and frequency. When combining the
recommendations on moderate and vigorous intensity
physical activity (PA), the daily minimum goal of PA should
be in the range of 64e107 METs/min.11
Recent studies have demonstrated that free living daily
PA levels in patients with IC are lower than in healthy
controls.13e16 However, PA is rarely used as an outcome
parameter in trials concerning IC treatment.15,17e21 It may
be relevant to study the potential beneﬁcial effects of SET
on PA level and exercise behavior in patients with IC. If PA
levels improve following SET, cardiovascular risk reduction
and improved QoL may follow in the long term.22,23
Although SET has proven effective in improving walking
distances,8,19 one can question whether an increased
walking capacity is of beneﬁt during the patient’s activities
of daily life. In other words, when a patient with IC is able to
walk further, this ﬁnding does not necessarily imply that PA
levels and/or exercise behavior are positively inﬂuenced. A
potential goal of future PAD treatment should, perhaps, be
aimed at increasing physical activity.
The aim of this study was to assess the effect of a SET
program on PA and walking behavior in an IC population. In
addition, it is hypothesized that a SET induced increased
walking distance would improve PA levels in patients
with IC.METHODS
The present study was run between January and September
2013. The study was conducted following a previous study
that was executed to quantify daily PA levels and energy
expenditure in patients newly diagnosed with IC.16
Patients were recruited from a population presenting
with new onset manifestations of IC at outpatient de-
partments of vascular surgery of the Catharina Hospital,
Eindhoven, and Maxima Medical Centre, Veldhoven/Eind-
hoven, the Netherlands. After taking histories and having a
physical examination, patients suspected of IC underwentan ankle-brachial index (ABI) measurement using standard
equipment. Patients with values < 0.90 at rest or a drop in
value of more than 0.15 after a standardized treadmill test
(at 3.2 km/h and a 10% incline) were considered eligible.
Exclusion criteria were serious cardiopulmonary limita-
tions (New York Heart Association class 3e4), critical limb
ischemia or previous lower limb amputation, use of walking
aids, psychiatric instability, or other serious comorbidity
that might have limited the patient’s walking ability. Pa-
tients who were treated with invasive revascularizations
during follow up were also excluded. Patients that were
willing to participate provided written informed consent. All
procedures described in this study were approved by the
medical ethical committee of Catharina Hospital,
Eindhoven.
Study protocol
All participants received detailed instructions on the spe-
ciﬁcs of proper handling and wearing of the DynaPort
MoveMonitor (McRoberts BV, The Hague, the Netherlands),
and were asked to wear the device correctly for 7 consec-
utive days. As the device is not waterproof, participants
were instructed to remove the device when taking a shower
or a bath. Participants were also asked to perform their
normal daily activities during this week and not to wear the
device during sleeping.
A 3 month period of SET was commenced immediately
after a 1 week monitoring period. Patients were referred to
a local physical therapist, who was trained in providing SET
according to the Royal Dutch Society for Physical Therapy
guidelines and the Dutch ClaudicatioNet network quality
standards.24 The educational program ensured that all pa-
tients received SET according to the guidelines of the Royal
Dutch Society for Physical Therapy.25 The physical therapist
assessed a baseline and a 3 month PFWD and MWD using a
standardized, graded treadmill protocol (walking at 3.2 km/
h) with a 0% incline that increased by 2% every 2 min to a
maximum of 10%).26,27 Patients were tested for a maximum
of 30 min (1,600 m). Evidence based cardiovascular risk
management, including antiplatelet and statin therapy, was
initiated as standard if patients were not taking this medi-
cation already. After 3 months, SET outcome was discussed
with the patient followed by a second 7 day period of
wearing the DynaPort MoveMonitor.
Monitoring of physical activity and walking impairment
The DynaPort MoveMonitor, a triaxial seismic accelerom-
eter, was used to measure PA. The DynaPort MoveMonitor
was placed in a belt that was strapped around the waist. It
was positioned at the base of the lumbar spine just cranial
to the buttocks. This accelerometer was chosen because of
an optimal correlation between indirect calorimetry and
generated MET output.28 Furthermore walking speed was
correctly measured in a population with chronic obstructive
pulmonary disease (COPD).28 Moreover, this activity
monitor was recently validated in an IC population.29 The
device consists of a triorthogonal-orientated piezo-
Eligible patients with a correct
baseline measurement
(n=126)
Exclusion (n=69)
- Not correct worn follow up measurement (n=17)
- refused a follow-up measurement (n=8)
- loss to follow up (n=38)
- SD card failure (n=6)
Eligible patients for analysis
(n=57)
Included patients for analysis
(n=41)
Not a solely SET regimen
- SET plus vascular surgery (n=10)
- “go home and walk advice” (n=6)
Figure 1. Study population ﬂowchart. Note. Correct worn ¼ the
device was “worn correctly” during a day if it detected a minimum
of 20 steps and if it was “worn” for  9 h and “not worn” for  5 h
a day; SD ¼ secure digital; SET ¼ supervised exercise therapy.
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removable secure digital card to store the acceleration data.
The raw acceleration data lend themselves to a pattern
recognition approach using logical algorithms (Move-
Monitor analysis software, version 2.6) for the classiﬁcation
of postures (lying, sitting, and standing) and motions
(locomotion and shufﬂing). The generalities and speciﬁcs of
the software have been published previously.16,29e31
A validated Dutch version of the Walking Impairment
Questionnaire (WIQ) and a 36-item Short Form Health
Survey version 2 (SF-36) were assessed at baseline and after
3 months of SET.32e34
Primary outcomes
The primary outcomes of the study were the percentage of
participants meeting the ACSM lower limit recommenda-
tion for PA and public health (67 METs/min/day); and the
percentage of participants meeting the ACSM higher limit
recommendation for PA and public health (107 METs/min/
day).
Secondary outcomes
The secondary outcomes were (i) daily PA level (measured
in METs/min); (ii) daily PA level performed in bouts of >
10 min of moderate or vigorous intensity (measured in
METs/min); (iii) mean time (min) spent per day during
different activities (lying, standing, sitting, walking, shuf-
ﬂing, locomotion, not wearing the device); (iv) mean
number of steps walked in one period and maximal number
per day (highest period of steps); and (v) activity per day
(min; sedentary activity: intensity < 1.5 METs; light: 1.5e
3.0 METs; moderate: 3e6 METs; vigorous: 6e9 METs).
Data analysis
Data checks per patient for each study day were deemed
necessary to ensure proper use of the device. By deﬁnition,
the device was ‘worn correctly’ during a day if it detected a
minimum of 20 steps and if it was ‘worn’ for  9 h and if it
was ‘not worn’ for  5 h a day. Moreover, to ﬁlter out
incorrect or unrepresentative data, patients were arbitrarily
excluded from analysis if the device was worn for < 5 days.
Mean time that was spent per day was determined for each
participant depending on the number of ‘correctly worn
days’. Analysis was performed on patients with both a
correct baseline and follow up measurement.
Statistical analyses
All analyses were performed using SPSS version 21 (IBM,
Armonk, NY, USA). Categorical variables were presented as
frequencies with percentages. A Pearson’s chi-square test
was used to identify differences for categorical variables. To
obtain an impression of the distribution, values were
analyzed for skewness and kurtosis. Nominal normally
distributed variables were depicted as the mean  SD,
while non-normally distributed values were reported as
median  interquartile range. Statistical differencesbetween the included and excluded study populations were
analyzed with an independent Student t test, while differ-
ences between time periods were calculated with a paired
sample t test or with Pearson correlation coefﬁcients for
continuous normally distributed variables. A Wilcoxon
signed-rank test or Spearman’s rho were utilized for non-
normally distributed continuous variables. A p-value < .05
was regarded as being statistically signiﬁcant.
RESULTS
Baseline characteristics
One hundred and twenty six patients with IC wore the
device correctly at baseline and were considered eligible for
this study (Fig. 1). At follow up, analysis of the accelerom-
eter data demonstrated that 17 patients did not wear the
device correctly for  5 days. In six cases the internal
memory card malfunctioned and data were not stored;
another eight participants refused a follow up measure-
ment; and another 38 were lost to follow up (36.5%). As a
consequence, the data of 57 participants was used for
analysis (45.2%); of these patients, 10 received a vascular
intervention during the study period and six did not receive
SET owing to inadequate healthcare insurance. The present
study reﬂects the results obtained from 41 patients (35.3%
of the total study population). Baseline characteristics
regarding both the included and excluded study population
are given in Table 1.
ACSM recommendations for patients with IC
Eighteen participants achieved the lower limit of the ACSM
recommendations (67 METs/min/day) and 12 of them also
met the ACSM upper limit (107 METs/min/day), even at
Table 1. Baseline characteristics.
Total study population (n ¼ 126) p
Included patients (n ¼ 41) Excluded patients (n ¼ 85)
Male sex, n (%) 20 (48.8) 49 (57.6) .45
Both legs symptomatic, n (%) 19 (46.3) 38 (44.7) .29
Age (years), mean  SD 69  11 68  10 .42
BMI (kg/m2), mean  SD 27.4  4.1 26.7  4.0 .37
Worst ABI at rest, mean  SD 0.61  0.20b 0.63  0.19c .50
Worst ABI after effort, mean  SD 0.43  0.21d 0.44  0.22e .85
Duplex right leg, n (%)a
No lesions 6 (14.6) NA
Aortoiliac 6 (14.6) NA
Femoropopliteal 12 (29.3) NA
Combination 5 (12.2) NA
Duplex left leg, n (%)a
No lesions 10 (24.4) NA
Aortoiliac 4 (9.8) NA
Femoropopliteal 12 (29.3) NA
Combination 5 (12.2) NA
Pulmonary history, n (%) 9 (22.0) 16 (18.8) .81
Cardiac history, n (%) 10 (24.4) 29 (34.1) .33
Note. BMI ¼ body mass index; ABI ¼ ankle-brachial index; NA ¼ not available.
a Values based on 29 patients.
b Values based on 38 patients.
c Values based on 82 patients.
d Values based on 30 patients.
e Values based on 73 patients.
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limit of the ACSM recommendations was signiﬁcantly lower
at baseline (n ¼ 18, 43%) compared with the numbers at
the 3 month follow up (n ¼ 26, 63%; p ¼ .003) (Fig. 2). Of
the initial 18 participants that achieved the lower limit of
the ACSM recommendations at baseline, 16 achieved the
lower limit at follow up (Fig. 2), while the remaining two did
not. Of the 12 participants who achieved the higher limit of
the ACSM recommendations at baseline (29%), eight ach-
ieved the higher limit again after 3 months (Fig. 2). In total,
14 patients met the ACSM’s higher limit (34%).Daily level of PA in patients with IC
Mean daily PA level (in METs/min) was normally distributed.
No signiﬁcant difference in mean daily PA level was foundFigure 2. Adherence to the American College of Sports Medicine’s (ACS
equivalents/day) at baseline and at the 3 month follow up (FU). Noteafter 3 months of SET (baseline: 395  220 METs/min vs. 3
months: 411  228 METs/min; p ¼ .430) (Fig. 3). Moreover,
daily PA levels performed in bouts of > 10 min were also
not signiﬁcantly different after 3 months (p ¼ .130; Fig. 3).
No signiﬁcant correlation coefﬁcients were found between
the change in mean daily PA (METs/min) or mean daily PA
in bouts and the increase in MWD (Dmean daily PA vs.
DMWD: r ¼ .210, p ¼ .190; Dmean daily PA in bouts vs.
DMWD: r ¼ .300, p ¼ .060).Time consumption and intensity of various activities
Table 2 depicts the time consumption and intensity of the
various daily activities of patients with IC. Data were non-
normally distributed. No signiﬁcant changes were found
after 3 months of SET. Analysis of the intensity levels did notM) minimum recommended level of physical activity (67 metabolic
. *p < .05.
Daily PA level Daily PA level in bouts
0
200
400
600
800 Baseline
3 months follow up
M
et
s 
* m
in
Figure 3. Mean daily physical activity (PA) level at baseline and at
the 3 month follow up. Note. Mets ¼ metabolic equivalents. *Data
were normally distributed and analyzed with a paired t test.
188 H.J.P. Fokkenrood et al.show any signiﬁcant differences between baseline and 3
month values (Table 2). However, the mean maximal
number of consecutive steps (top period of steps), which
was normally distributed, was signiﬁcantly higher after 3
months of SET (1,914  1,473 vs. 2,390  1,904; p < .050).Walking distances and QoL
PFWD, MWD and total WIQ score signiﬁcantly improved
following SET (Table 3). Moreover, QoL, as reﬂected by SF-
36 scores, showed a signiﬁcant increase in the physical
functioning (PF) and the bodily pain (BP) role (Table 3). No
signiﬁcant correlation was found between the increase in
both QoL roles and an improvement in MWD (DPF vs.
DMWD: r ¼ .070, p ¼ .750; DBP vs. DMWD: r ¼ .080,
p ¼ .730).
DISCUSSION
In line with the current interest in studying potential as-
sociations between daily PA and its impact on cardiovas-
cular risk reduction and mortality,35e41 this study assesses
the effect of SET on the proportion of patients with ICTable 2. Mean daily activities and duration at different intensity level
Baseline (n ¼ 41), median (IQR)
Device worn correctly (d) 7 (6e7)
Time worn (min) 910 (880e1006)
Lying 139 (72e270)
Sitting 462 (390e580)
Standing 151 (108e221)
Walking 64 (40e87)
Shufﬂing 20 (13e25)
Locomotion 89 (61e116)
Not worn (min) 529 (434e559)
Steps (mean  SD) 5,732 (3187)
Highest period consecutive
steps (mean  SD)
1,914 (1473)
Light activity (min) 66 (50e91)
Moderate activity (min) 83 (59e107)
Vigorous activity (min) 1.3 (0.4e6.2)
Note. IQR ¼ interquartile range; light activity ¼ activity with an
activity ¼ activity with an intensity of 3.1e6.0 METs; vigorous activity
a Wilcoxon signed rank test.
b Paired t test.meeting the ACSM recommended lower and higher limits
for PA and public health. Several studies have registered
activity levels in patients with IC.15,17e21 However, this
parameter was never considered as a primary outcome
value. McDermott et al. showed, in a 7 day measurement
model, that patients with IC had signiﬁcantly improved PA
levels (in activity units) after 6 months of home based ex-
ercise.21 These ﬁndings might, in part, be conﬁrmed by the
present results. Although our study was based on a shorter
follow up period and based on supervised therapy, SET
increased the percentage of patients with IC achieving the
ACSM recommended lower and higher limit of daily PA
level.11 However, ﬁrm conclusions cannot be drawn, as
some patients showed a decline in PA level, and mean
values for ambulatory activities (e.g., walking time, total
number of steps) were not inﬂuenced after a period of SET.
Probably, large variations in activities per patient (duration,
as well as intensity) and between patients in combination
with the relatively small study population could have
caused this contradiction. Therefore, further research is
necessary to optimize the assessment of PA levels in pa-
tients with IC. However, from the present results, it could be
argued that a 3 month SET program may have beneﬁcial
effects on increasing daily PA in an IC population.
It was hypothesized that an increased walking capacity
would result in an improved PA level in patients with IC.
Although both the percentage of patients meeting the
ACSM limits and walking capacity signiﬁcantly improved
after 3 months of SET, no signiﬁcant correlation between
the change in PA levels and the increase in walking distance
was found. Therefore, it may be argued that components of
a SET program other than an increased walking capacity
inﬂuence daily PA. The ﬁndings of the present study might
suggest that solely focusing on improvement of walking
capacity has a limited value in optimizing SET treatment
efﬁcacy. It appears that patients who are able to walk
further (because of a decrease in IC symptoms) will not uses at baseline and at the 3 month follow up.
3 month follow up (n ¼ 41), median (IQR) p
7 (6e7)
932 (899e1043) .06a
182 (99e270) .27a
512 (397e607) .24a
168 (123e209) .40a
61 (42e88) .87a
17 (13e32) .70a
82 (60e125) .84a
509 (397e541) .11a
5,805 (3336) .43b
2,390 (1904) .03b
64 (51e91) .29a
81 (58e106) .81a
0.9 (0.4e7.9) .97a
intensity of 1.5e3.0 metabolic equivalents (METs); moderate
¼ activity with an intensity of 6.1e9.0 METs.
Table 3. Quality of life and walking distances at baseline and at the 3 month follow up.
Baseline, median (IQR) 3 month follow up, median (IQR) p
PFWD (m)a 210 (113e300) 390 (230e580) .001d
MWD (m)b 373 (254e631) 637 (403e1,045) <.001d
WIQ total scorec 0.33 (0.16e0.58) 0.54 (0.41e0.78) <.001d
SF-36c
Physical functioning 36.0 (25.5e43.9) 38.1 (33.9e46.5) .002d
Physical role 42.2 (30.5e48.9) 39.8 (32.8e52.0) .120d
Bodily pain 41.4 (37.2e49.3) 46.1 (37.2e50.3) .040d
General health 41.7 (36.8e49.3) 44.8 (38.2e51.8) .060d
Vitality 49.0 (43.5e61.5) 52.1 (45.8e60.7) .350d
Social role 45.9 (35.0e56.8) 51.4 (40.5e56.8) .110d
Emotional role 48.1 (40.3e55.9) 44.2 (36.0e55.9) .340d
Mental health 52.8 (44.0e61.3) 55.6 (42.3e58.5) .850d
Note. IQR ¼ interquartile range; PFWD ¼ pain free walking distance; MWD ¼ maximal walking distance; WIQ ¼ Walking Impairment
Questionnaire; SF-36 ¼ Short Form Health Survey version 2.
a Values based on 34 patients.
b Values based on 40 patients.
c Values based on 39 patients.
d Wilcoxon signed rank test.
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intensity in daily life.
The effect of SET on QoL is still the subject of debate.8 A
recently published meta-analysis found a positive trend in
improved QoL after 3 months of SET, although only the SF-
36 “general health” role appeared signiﬁcantly increased.8
In addition, McDermott et al. found no group differences
in changes in the SF-12 physical component summary or
mental component summary subscales.21 In contrast, the
present study found a signiﬁcant increase in both the
physical functioning and the bodily pain role after 3 months
of SET. Although patients showed an increased walking
capacity, no signiﬁcant correlation in the change of SF-36
values was found. This ﬁnding was recently conﬁrmed by
others reporting that the improvement in self-efﬁcacy,
satisfaction with functioning, pain acceptance, and social
functioning after 6 months of home based walking exercise
compared with a non-exercising control group was inde-
pendent of walking performance.42 In combination with the
ﬁnding of the present study that walking capacity might be
of diminished value, a shift in SET treatment paradigm
seems necessary. Future research should therefore focus on
the optimization of SET programs other than increasing
walking capacity alone (intrinsic motivation, lifestyle, pa-
tient satisfaction and expectations, social functioning, etc.).
Unfortunately, a number of participants were lost to
follow up, which may have potentially resulted in a selec-
tion bias. However, this is probably not the case, as there
were no differences in baseline characteristics between the
study group and excluded patients. Furthermore, both
study groups were a representative reﬂection of the general
PAD population encountered in a vascular outpatient clinic.
An important reason for this substantial loss to follow up is
the fact that 56 of the 126 included patients were recruited
from a previously performed study.16 Only 23 of these 56
patients were eligible for inclusion because the 3 month
follow up period had expired in the others. Furthermore,
introducing the Dynaport MoveMonitor from a researchsetting to daily practice in an outpatient clinic may boost
wear compliance, as was observed in comparable research
concerning patients with COPD.43 Unfortunately, a reliable
sub-analysis between revascularization and SET treatment
could not be performed, as only 16 participants received
such a treatment. Further research is needed to identify the
effect of different IC treatment modalities on daily PA levels
and ambulatory activities.
CONCLUSION
A 3 month SET program increased the number of patients
achieving the ACSM/AHA public health minimum recom-
mendations for PA. The general focus of solely increasing
walking capacity seemed ancillary to other elements of
supervision. Further research is needed to determine the
optimal content of a SET program. In concert with the in-
terest in factors such as sedentary activities and cardio-
vascular event risks, exercise behavior and PA might be
included as outcome parameter in future PAD research and
eventually clinical practice.
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